VOYA Investment Management
KRYS icon

VOYA Investment Management’s Krystal Biotech KRYS Stock Holding History

VOYA Investment Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.3M Buy
124,442
+16,045
+15% +$4.79M 0.04% 324
2026
Q1 		$28M Buy
108,397
+5,136
+5% +$1.37M 0.03% 400
2025
Q4 		$25.5M Buy
103,261
+9,353
+10% +$1.97M 0.03% 456
2025
Q3 		$16.6M Buy
93,908
+29,915
+47% +$4.48M 0.02% 539
2025
Q2 		$8.8M Sell
63,993
-608
-0.9% -$89.3K 0.01% 767
2025
Q1 		$11.6M Sell
64,601
-10,100
-14% -$1.7M 0.01% 691
2024
Q4 		$11.7M Buy
74,701
+4,123
+6% +$731K 0.01% 702
2024
Q3 		$12.8M Sell
70,578
-4,174
-6% -$805K 0.01% 690
2024
Q2 		$13.7M Buy
74,752
+14,027
+23% +$2.36M 0.01% 659
2024
Q1 		$10.8M Buy
60,725
+13,128
+28% +$1.82M 0.01% 731
2023
Q4 		$5.9M Buy
47,597
+19,157
+67% +$2.12M 0.01% 938
2023
Q3 		$3.3M Sell
28,440
-12,900
-31% -$1.57M ﹤0.01% 1136
2023
Q2 		$4.85M Buy
41,340
+8,186
+25% +$836K 0.01% 1005
2023
Q1 		$2.65M Sell
33,154
-29,455
-47% -$2.31M ﹤0.01% 1236
2022
Q4 		$4.96M Sell
62,609
-1,577
-2% -$117K 0.01% 965
2022
Q3 		$4.47M Buy
64,186
+56,408
+725% +$4.08M 0.01% 1001
2022
Q2 		$511K Buy
7,778
+766
+11% +$47.7K ﹤0.01% 1826
2022
Q1 		$467K Hold
7,012
– – ﹤0.01% 1957
2021
Q4 		$490K Sell
7,012
-49,223
-88% -$2.87M ﹤0.01% 2028
2021
Q3 		$2.94M Sell
56,235
-4,280
-7% -$253K 0.01% 1020
2021
Q2 		$4.12M Sell
60,515
-29,555
-33% -$2.06M 0.01% 934
2021
Q1 		$6.94M Sell
90,070
-14,213
-14% -$1.03M 0.01% 721
2020
Q4 		$6.26M Sell
104,283
-8,190
-7% -$409K 0.01% 740
2020
Q3 		$4.84M Buy
112,473
+21,661
+24% +$941K 0.01% 763
2020
Q2 		$3.76M Buy
90,812
+19,017
+26% +$915K 0.01% 840
2020
Q1 		$3.1M Sell
71,795
-9,351
-12% -$489K 0.01% 827
2019
Q4 		$4.49M Sell
81,146
-118,005
-59% -$5.79M 0.01% 840
2019
Q3 		$6.92M Buy
+199,151
New +$8.9M 0.02% 707

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

VOYA Investment Management's KRYS Position: Q2 2026 in Review

VOYA Investment Management increased its Krystal Biotech (KRYS) stake by 15% in Q2 2026, buying an estimated $4.79M and bringing the position to 124,442 shares worth $46.3M. The position accounts for 0.04% of the portfolio, ranked #324.

VOYA Investment Management first reported a position in KRYS in Q3 2019 and has held it in 28 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • VOYA Investment Management held 124,442 shares of Krystal Biotech worth $46.3M as of Q2 2026.
  • VOYA Investment Management bought 16,045 Krystal Biotech shares in Q2 2026, an estimated $4.79M.
  • Krystal Biotech made up 0.04% of VOYA Investment Management's portfolio in Q2 2026, its #324 holding.
  • VOYA Investment Management first reported a position in Krystal Biotech in Q3 2019 and has held it in 28 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.